Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis

Endocrine Reviews

Volumn 21, Issue 2, 2000, Pages 115-137

  Manolagas, Stavros C ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; BONE CELL; BONE MASS; BONE METABOLISM; BONE REGENERATION; CELL DEATH; CELL MATURATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; BONE AND BONES; CYTOKINES; HORMONES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 0034455103     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.21.2.115     Document Type: Review

References (266)

1. Involutional osteoporosis
2. Sex steroids in the pathogenesis and prevention of osteoporosis
3. Bone density and fracture risk in men
4. Osteoporosis in men
5. Glucocorticoid effects on bone
6. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group
7. Evidence for two distinct syndromes of involutional osteoporosis
8. The two-stage concept of bone loss revisited
9. Hyperparathyroidism
10. Skeletal heterogeneity and the purposes of bone remodeling: Implications for the understanding of osteoporosis
11. A new model of cancellous bone growth
12. Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone
13. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo
14. Lineage of osteogenic cells and their relationship to the stromal system
15. The stem cell of the osteoblast
16. Advances in bone biology: The osteoclast
17. Modulation of osteoclast differentiation
18. Multilineage potential of adult human mesenchymal stem cells
19. Pericyte differentiation
20. Bone marrow, cytokines, and bone remodelingemerging insights into the pathophysiology of osteoporosis
21. Bone morphogenetic proteins
22. Essential requirement of BMPs 2/4 for both osteoblast and osteoclast formation in bone marrow cultures from adult mice: Antagonism by noggin
23. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation
24. Potential role of Cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF)
25. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts
26. Stage-specific expression of Dlx-5 during osteoblast differentiation: Involvement in regulation of osteocalcin gene expression
27. Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5
28. A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction
29. Skeletal Growth Factors
30. Role of active and latent transforming growth factor β in bone formation
31. Dorsoventral patterning in Xenopus: Inhibition of ventral signals by direct binding of chordin to BMP-4
32. The Xenopus dorsalizing factor noggin ventralizes Drosophila embryos by preventing DPP from activating its receptor
33. Identification of mammalian noggin and its expression in the adult nervous system
34. Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer
35. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4
36. Competition between noggin and bone morphogenic protein 4 activities may regulate dorsalization during Xenopus development
37. Interleukin-6-type cytokines and their receptors
38. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation
39. The role of IL-6 type cytokines and their receptors in bone
40. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens
41. Platelet-derived growth factor stimulates the synthesis of interleukin-6 in cells of the osteoblast lineage
42. Platelet-derived growth factor induces interleukin-6 transcription in osteoblasts through the activator protein-1 complex and activating transcription factor-2
43. The alphas, betas, and kinases of cytokine receptor complexes
44. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components
45. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors
46. STATs and gene regulation
47. Soluble forms of the interleukin-6 signal-transducing receptor component gpl30 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
48. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors
49. 3 or parathyroid hormone
50. Increased osteoclast development after estrogen loss: Mediation by interleukin-6
51. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
52. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells
53. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation
54. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage
55. Developmental abnormalities in mice transgenic for bovine oncostatin M
56. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death
57. Transforming growth factor-β
58. 1 knockout mice: A mutation in one cytokine gene causes a dramatic inflammatory disease
59. Cells of bone: Osteoclast generation
60. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome
61. Calcitonin receptor isoforms in mouse and rat osteoclasts
62. Hormonal regulation of osteoclast function
63. Interleukin-11: A new cytokine critical for osteoclast development
64. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption
65. A role of interleukin-6 in parathyroid hormone-induced bone resorption in vivo
66. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: The role of the androgen receptor
67. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders
68. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site (Inr motif) occlusion
69. Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro
70. Osteopontin overview
71. Cell surface attachment molecules in bone
72. Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: Demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy
73. Differentiation and transforming growth factor-β re ceptor down-regulation by collagen-αβ1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells
74. Inability of collagenase to cleave type I collagen in vivo is associated with osteocyte apoptosis
75. Fibronectin is a survival factor for differentiated osteoblasts
76. Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the osf2 transcription factor
77. Vβ3 potentiate bone resorption
78. Stromal stem cells: Marrow-derived osteogenic precursors
79. Association of alkaline-phosphatasepositive reticulum cell in bone marrow with granulocyte precursors
80. Bone marrow
81. Alkaline phosphatase positive precursors of adipocytes in the human bone marrow
82. In vivo distribution of parathyroid hormone receptors in bone: Evidence that a predominant osseous target cell is not the mature osteoblast
83. Marrow stromal (Western-Bainton) cells: Identification, morphometry, confocal imaging and changes in disease
84. Adipocytic cells cultured from marrow have osteogenic potential
85. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells
86. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins
87. Adipogenesis and obesity: Rounding out the big picture
88. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids
89. Peroxisome proliferator activated receptor γ, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation
90. The CCAAT/enhancer binding protein and its role in adipocyte differentiation: Evidence for direct involvement in terminal adipocyte development
91. Ectopic expression of the CCAAT/enhancer-binding protein a promotes the adipogenic program in a variety of mouse fibroblastic cells
92. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor
93. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR γ2
94. Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR γ and C/EBP α
95. Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages
96. Theoretical and methodological approach
97. The role of IGF-1 in the coupling of bone formation to resorption
98. Latent forms of transforming growth factor-β (TGFβ) derived from bone cultures: Identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGFβ
99. Coupling of bone resorption and formation during bone remodeling
100. Dissociation between bone resorption and bone formation in osteopenic transgenic mice
101. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells
102. Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells
103. Murine bone marrow stromally derived BMS2 adipocytes support differentiation and function of osteoclast-like cells in vitro
104. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence
105. The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage
106. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
107. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
108. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
109. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
110. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
111. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
112. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
113. To die or not to die-the quest of the TRAIL receptors
114. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
115. Identification of an OSF-2 binding site in the murine RANKL/OPGL gene promoter: A potential link between osteoblastogenesis and osteoclastogenesis
116. Cell number vs. cell vigor-what really matters to a regenerating skeleton?
117. New developments in the pathogenesis and treatment of steroid-induced osteoporosis
118. Control of osteoclast differentiation
119. The biochemistry of bone
120. Increased bone formation in osteocalcin-deficient mice
121. Osteonectin-null mice develop severe osteopenia
122. Biomineralization: Conflicts, challenges, and opportunities
123. Matrix proteins and mineralization: An overview
124. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization
125. Structure-function relationships in the osteocyte
126. The Osteocyte
127. The structure of bone tissues and the cellular control of their deposition
128. Function of osteocytes in bone
129. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of their deleterious effects on bone
130. The role of estrogen in the control of rat osteocyte apoptosis
131. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone
132. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates
133. Proteolytic activity of human osteoclast cathepsin Kexpression, purification, activation, and substrate identification
134. Trafficking of matrix collagens through bone-resorbing osteoclasts
135. Removal of osteoclast bone resorption products by transcytosis
136. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells
137. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis
138. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β
139. Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines
140. Mechanisms and genes of cellular suicide
141. Bone-forming cells in clinical conditions
142. In vivo osteocyte death
143. Identification of apoptotic changes in osteocytes in normal and pathological human bone
144. Apoptosis in bone physiology and disease
145. WAF1,CIP1,SD11 gene by interleukin-6 type cytokines - A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells
146. Guanine nucleotide bindingprotein coupled signaling pathway regulation of osteoblast-mediated bone formation
147. Osteoclast biology
148. Regulation of osteoclast function
149. Osteocalcin gene promoter: Unlocking the secrets for regulation of osteoblast growth and differentiation
150. Regulation of osteoclast activity
151. Stem cell concepts
152. Calcitonin alters behavior of isolated osteoclasts
153. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
154. Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion
155. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial
156. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
157. Infection with TRANCE-expressing retrovirus for the generation of osteoclastic cell lines
158. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats
159. Cellular and molecular mechanisms of osteoporosis
160. Cytokines, bone remodeling, and estrogen deficiency: A 1998 update
161. Cytokines, estrogen, and postmenopausal osteoporosisthe second decade
162. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow
163. Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone
164. Endogenous bone-resorbing factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6
165. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement
166. In vitro secretion of cytokines by human bone marrow: Effects of age and estrogen status
167. Cytokine production in the bone marrow microenvironment: Failure to demonstrate estrogen regulation in early postmenopausal women
168. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone
169. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
170. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
171. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
172. Serum cytokines in thyrotoxicosis
173. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome
174. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow: Evidence for autonomy from factors released during bone resorption
175. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of egr-1 and its interaction with Sp-1
176. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD
177. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells
178. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period
179. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice
180. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency
181. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
182. Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women
183. Opposite effects of estrogen on the life span of osteoblasts/osteocytes vs. osteoclasts in vivo and in vitro: An explanation of the imbalance between formation and resorption in estrogen deficiency
184. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
185. Effect of testosterone and estradiol in a man with aromatase deficiency
186. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency
187. Unitary model of osteoporosis revisited
188. 5α-reductase deficiency and complete androgen insenstitivity: Natural models to suggest a direct role for androgens on bone density in men
189. Like estrogen, androgen exert potent and direct anti-apoptotic effects on osteoblasts and osteocytes in vivo and in vitro
190. Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age
191. Relations between histologic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis
192. Effects of ethnicity and age or menopause on osteoblast function, bone mineralization, and osteoid accumulation in iliac bone
193. Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers
194. Relationship of bone turnover to bone density and fractures
195. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study
196. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
197. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow
198. The effect of age on the osteogenic potential of human bone marrow stromal cells
199. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia
200. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
201. PPAR7 promotes monocyte/macrophage differentiation and uptake of oxidized LDL
202. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders
203. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells
204. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: Links between osteoporosis and cardiovascular disease?
205. Comparison of the bone mineral content of the lower limbs in men with ischaemic atherosclerotic disease
206. Genetic mapping of loci conferring osteopenia using closely-related mouse strains
207. Quantitative trait loci affecting peak bone mineral density in mice
208. Identification of peak bone mass QTL in a spontaneously osteoporotic mouse strain
209. Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 levels in aging and age-associated diseases
210. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
211. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: A stereological study
212. The function of adipocytes in the bone marrow stroma: An update
213. Fatty involution of marrow and the role of adipose tissue in hemopoiesis
214. Increased hematopoiesis accompanies reduced osteoblastogenesis in the senescence-accelerated mouse (SAM-P/6)
215. Glucocorticoid-induced osteoporosis
216. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
217. Increased bone formation by prevention of osteoblast apoptosis with PTH
218. Prevention of osteocyte and osteoblasts apoptosis by bisphosphonates and calcitonin
219. Nontraumatic necrosis of bone (osteonecrosis)
220. Anatomic juxtaposition of apoptotic osteocytes and avascular necrosis in femurs from patients with glucocorticoid-excess
221. Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid
222. Opposing effects by glucocorticoid and bone morphogenetic protein-2 in fetal rat bone cell cultures
223. Inhibitory actions of glucocorticoids on skeletal growth. Is local insulin-like growth factor I to blame?
224. Glucocorticoids induce adipogenesis of stromal cells by transcriptionally activating PPARy2
225. Anabolic actions of parathyroid hormone on bone
226. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration
227. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial
228. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial
229. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis
230. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis
231. PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis
232. Sphingosine kinase mediates cyclic AMP suppression of apoptosis in rat periosteal cells
233. Apoptosis mediated by the PTH/PTHrP receptor: Role of JNK and calcium signaling pathways
234. Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34)
235. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
236. Stemming bone loss by suppressing apoptosis
237. Bisphosphonates: Pharmacology and use in the treatment of osteoporosis
238. Calcitonin
239. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
240. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
241. Bisphosphonates: Mechanisms of action
242. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs
243. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
244. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates
245. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis
246. Therapeutic potential of TGF-beta, BMP, and FGF in the treatment of bone loss
247. Growth hormone, insulin-like growth factors
248. Essential requirement of the estrogen receptor alpha or beta for (non-genomic) anti-apoptotic effects of estrogen
249. Estrogen inhibit apoptosis of osteoblasts and osteocytes through rapid (non-genomic) activation of extracellular signal-regulated kinases (ERKs)
250. Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional normuclear receptors
251. Rapid activation of MAP kinase by estrogen in the bone cell line
252. Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription
253. Estrogen actions in the central nervous system
254. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen
255. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis
256. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells
257. Membrane estrogen receptors identified by multiple antibody labeling and impededligand binding
258. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERα and ERβ expressed in Chinese hamster ovary cells
259. Estrogen receptor-alpha detected on the plasma membrane of aldehydefixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry
260. Activators of non-genomic estrogen-like signalling (ANGELS): A novel class of small molecules with bone anabolic properties
261. Effects of estradiol-17β analogues on activation of estrogen response element regulated chloramphenicol acetyltransferase expression
262. Relationship between estrogen structure and conformational changes in estrogen receptor/DNA complexes
263. Nuclear estrogen receptor-independent neuroprotection by estratrienes: A novel interaction with glutathione
264. Phenolic A ring requirement for the neuroprotective effects of steroids
265. Effects of 17β-estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in the rats